Breaking Finance News

Goldman Sachs Group Inc. recorded Pacira Pharmaceuticals Inc (NASDAQ:PCRX), upping its target price to $36.00 today

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) had its target price raised to $36.00 by Goldman Sachs Group Inc. in a report issued Thursday December 01, 2016. The updated stock price target implies a possible upside of 0.13% from the company's most recent close.

Having a price of $31.85, Pacira Pharmaceuticals Inc (NASDAQ:PCRX) traded -4.08% lower on the day. With the last close down -20.93% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Pacira Pharmaceuticals Inc has recorded a 50-day average of $34.12 and a two hundred day average of $38.64. Volume of trade was up over the average, with 1,037,143 shares of PCRX changing hands over the typical 835,594

Performance Chart

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

With a total market value of $0, Pacira Pharmaceuticals Inc has with a one year low of $30.00 and a one year high of $80.25 .

A total of 9 analysts have released a research note on Pacira Pharmaceuticals Inc. Five analysts rating the company a strong buy, four analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $82.22.

More About Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *